Ubs Group Ag Salarius Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.17 - $0.25 $244 - $359	-1,437 Reduced 3.4%	40,848 $8,000
Q2 2022 Aug 10, 2022	BUY	$0.16 - $0.42 $6,365 - $16,709	39,785 Added 1591.4%	42,285 $9,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.01 $1,911 - $3,939	-3,900 Reduced 60.94%	2,500 $1,000
Q3 2021 Nov 15, 2021	SELL	$0.8 - $1.15 $80 - $114	-100 Reduced 1.54%	6,400 $7,000
Q2 2021 Aug 13, 2021	SELL	$1.02 - $1.52 $6,200 - $9,240	-6,079 Reduced 48.33%	6,500 $7,000

Q1 2021 May 12, 2021	BUY	$1.0 - $3.0 $12,579 - $37,737	12,579 New	12,579 $19,000
Q2 2020 Jul 31, 2020	SELL	$0.6 - $1.82 $6,673 - $20,243	-11,123 Closed	0 $0
Q1 2020 May 01, 2020	BUY	$0.56 - $3.82 $5,741 - $39,166	10,253 Added 1178.51%	11,123 $8,000
Q4 2019 Feb 14, 2020	SELL	$3.02 - $5.9 $6,837 - $13,357	-2,264 Reduced 72.24%	870 $3,000
Q3 2019 Nov 14, 2019	BUY	$5.28 - $20.25 $16,547 - $63,463	3,134 New	3,134 $17,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.1M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.